The anticonvulsant drugs levetiracetam, fosphenytoin and valproate all demonstrate efficacy for benzodiazepine-refractory convulsive status epilepticus, with each drug inducing seizure cessation and improving alertness in most patients and yielding similar safety outcomes, according to data from the Established Status Epilepticus Treatment Trial (ESETT).
The concurrent use of metformin with the tyrosine kinase inhibitor (TKI) gefitinib does more harm than good, resulting in significantly worse outcomes and increasing the risk of diarrhoea in nondiabetic patients with nonsmall cell lung cancer (NSCLC) harbouring EFGR mutation, according to data from a phase II trial.
In the treatment of paediatric patients with postdural puncture headache refractory to conservative therapies, the use of cosyntropin results in rapid pain relief, according to data from a retrospective analysis.
Treatment with antiepileptic drugs does not increase the risk of skin cancer, but an association has been observed between use of carbamazepine and lamotrigine and squamous cell carcinoma (SCC), a recent study has shown.
Use of ustekinumab in the treatment of systemic lupus erythematosus leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.
Elderly patients with cognitive impairment may have trouble understanding and complying with medical instructions provided during hospitalization, suggests a study. Pharmacy students, however, can perform Mini-Cog assessments to examine cognitive function, which allow them to tailor education content and involve caregivers when needed.
The use of ipilimumab with stereotactic radiotherapy, either concurrently or sequentially, yields satisfactory outcomes with low toxicities in patients with metastatic cancer, according to the results of a phase II trial.
Among community-dwelling patients diagnosed with dementia, less than a third have benefitted from antipsychotic treatment, while more than half endure a higher risk of adverse events, according to a recent study.
In the management of patients with generalized anxiety disorder (GAD), vortioxetine proves to be safe and well tolerated but exerts neutral effects on GAD symptoms, quality of life (QoL) and functional status, according to the results of a meta-analysis.